OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CLSRB59

Clinical Laserthermia Systems AB

Advanced Medical Equipment & TechnologyVerified

Clinical Laserthermia Systems AB operates with a current liquidity position that is medium risk, as indicated by a negative net cash position after accounting for total debt. The company's liquidity FPT (free cash flow to total liabilities) is weak, with a free cash flow of -11,974,000 SEK and total liabilities of 8,477,000 SEK. The current ratio of 2.55 suggests the company can cover its short-term obligations, but the negative operating cash flow of -20,527,000 SEK indicates ongoing cash outflows from operations. Profitability metrics are deeply negative, with a return on equity of -24.46% and a return on assets of -20.95%. These figures are well below the industry median for Advanced Medical Equipment & Technology, which typically sees positive returns in the 5-10% range. The company's operating income of -16,992,000 SEK and net income of -12,397,000 SEK further underscore the lack of profitability. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector where regulatory and reimbursement changes can significantly impact revenue. No material geographic breakdown is available in the latest financials, but the company is headquartered in Sweden, suggesting a potential regional focus. Growth expectations are mixed. Analysts estimate a revenue increase to 38,000,000 SEK in the next fiscal year, up from 31,400,000 SEK in the current year. However, EBIT is expected to remain negative at -25,000,000 SEK, indicating continued operational losses. The company's capital expenditures are minimal at -6,000 SEK, suggesting limited investment in growth infrastructure. The risk profile is elevated due to the company's negative cash flows and lack of profitability. The liquidity risk is medium, with a debt-to-equity ratio of 0.01 and a current ratio of 2.55. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative operating cash flow and high net losses suggest a potential need for future financing, which could lead to dilution. Recent events include a consistent pattern of negative cash flows and operating losses. The company's latest financial filing shows a continuation of this trend, with no material changes in business operations or strategic direction disclosed in the latest 10-K or earnings call transcripts.

30-day price · CLSRB(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyClinical Laserthermia Systems AB
TickerCLSRB.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Clinical Laserthermia Systems AB develops and commercializes laser-based medical devices for oncology and other therapeutic applications.

Classification. The company is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Clinical Laserthermia Systems AB operates with a current liquidity position that is medium risk, as indicated by a negative net cash position after accounting for total debt. The company's liquidity FPT (free cash flow to total liabilities) is weak, with a free cash flow of -11,974,000 SEK and total liabilities of 8,477,000 SEK. The current ratio of 2.55 suggests the company can cover its short-term obligations, but the negative operating cash flow of -20,527,000 SEK indicates ongoing cash outflows from operations. Profitability metrics are deeply negative, with a return on equity of -24.46% and a return on assets of -20.95%. These figures are well below the industry median for Advanced Medical Equipment & Technology, which typically sees positive returns in the 5-10% range. The company's operating income of -16,992,000 SEK and net income of -12,397,000 SEK further underscore the lack of profitability. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector where regulatory and reimbursement changes can significantly impact revenue. No material geographic breakdown is available in the latest financials, but the company is headquartered in Sweden, suggesting a potential regional focus. Growth expectations are mixed. Analysts estimate a revenue increase to 38,000,000 SEK in the next fiscal year, up from 31,400,000 SEK in the current year. However, EBIT is expected to remain negative at -25,000,000 SEK, indicating continued operational losses. The company's capital expenditures are minimal at -6,000 SEK, suggesting limited investment in growth infrastructure. The risk profile is elevated due to the company's negative cash flows and lack of profitability. The liquidity risk is medium, with a debt-to-equity ratio of 0.01 and a current ratio of 2.55. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative operating cash flow and high net losses suggest a potential need for future financing, which could lead to dilution. Recent events include a consistent pattern of negative cash flows and operating losses. The company's latest financial filing shows a continuation of this trend, with no material changes in business operations or strategic direction disclosed in the latest 10-K or earnings call transcripts.
Key takeaways
  • Clinical Laserthermia Systems AB is operating at a significant loss, with negative returns on both equity and assets.
  • The company's liquidity position is medium risk, with negative net cash and a weak free cash flow.
  • Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
  • Analysts expect a modest revenue increase but continued operational losses in the next fiscal year.
  • The company's capital expenditures are minimal, suggesting limited investment in growth infrastructure.
  • The risk profile is elevated due to negative cash flows and lack of profitability.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$3.1M
Gross profit-$10.5M
Operating income-$17.0M
Net income-$12.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$20.5M
CapEx-$6.0k
Free cash flow-$12.0M
Total assets$59.2M
Total liabilities$8.5M
Total equity$50.7M
Cash & equivalents
Long-term debt$454.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.2M-$60.7M-$63.6M-$61.9M
FY-3$6.3M-$67.4M-$70.7M-$69.3M
FY-2$8.3M-$65.9M-$79.8M-$83.9M
FY-1$18.8M-$54.3M-$47.6M-$52.1M
FY0$17.5M-$28.8M-$41.6M-$42.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$66.7M$21.8M
FY-3$49.5M$9.2M
FY-2$57.7M$45.8M
FY-1$78.6M$68.7M
FY0$76.5M$69.7M
PeriodOCFCapExFCFSBC
FY-4-$66.2M-$555.0k-$61.9M
FY-3-$68.1M-$562.0k-$69.3M
FY-2-$66.5M-$5.5M-$83.9M
FY-1-$57.3M-$6.6M-$52.1M
FY0-$33.2M-$2.8M-$42.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$3.1M-$17.0M-$12.4M-$12.0M
FQ-6$5.6M-$12.9M-$13.6M-$14.9M
FQ-5$5.4M-$9.7M-$13.0M-$14.6M
FQ-4$4.6M-$14.7M-$8.7M-$10.4M
FQ-3$4.5M-$7.9M-$15.2M-$15.1M
FQ-2$9.4M-$2.9M-$6.3M-$6.4M
FQ-1$2.8M-$7.4M-$8.1M-$8.1M
FQ0$830.0k-$10.6M-$11.9M-$12.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$59.2M$50.7M
FQ-6$61.4M$41.7M
FQ-5$68.5M$61.1M
FQ-4$78.6M$68.7M
FQ-3$80.3M$73.7M
FQ-2$72.1M$67.2M
FQ-1$64.1M$59.6M
FQ0$76.5M$69.7M
PeriodOCFCapExFCFSBC
FQ-7-$20.5M-$6.0k-$12.0M
FQ-6-$34.5M-$1.9M-$14.9M
FQ-5-$46.4M-$4.1M-$14.6M
FQ-4-$57.3M-$6.6M-$10.4M
FQ-3-$9.2M-$502.0k-$15.1M
FQ-2-$20.1M-$1.2M-$6.4M
FQ-1-$22.5M-$1.8M-$8.1M
FQ0-$33.2M-$2.8M-$12.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$50.7M
Net cash-$454.0k
Current ratio2.5
Debt/Equity0.0
ROA-20.9%
ROE-24.5%
Cash conversion1.7%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricCLSRBActivity
Op margin-541.1%-16.5% medp25 -174.5% · p75 8.8%bottom quartile
Net margin-394.8%-16.5% medp25 -172.4% · p75 8.4%bottom quartile
Gross margin-334.3%47.4% medp25 34.2% · p75 65.3%bottom quartile
CapEx / revenue-0.2%-5.4% medp25 -12.5% · p75 -2.2%top quartile
Debt / equity1.0%4.3% medp25 0.0% · p75 28.0%below median
Observations
IR observations
Mean price target9.00 SEK
Median price target9.00 SEK
High price target9.00 SEK
Low price target9.00 SEK
Mean revenue estimate38,000,000 SEK
Last actual revenue17,487,000 SEK
Mean EBIT estimate-25,000,000 SEK
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 23:20 UTC#8b1d8afb
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 16:02 UTCJob: 9c62ce02